Delled – LaFleur was already one of the pioneers of the medical cannabis sector in France. The company has just announced that it has cultivated and released a batch of medical cannabis extract intended for manufacturing an oral form of cannabis treatment. This milestone marks a turning point in the history of the company and that of medical cannabis in France, which is inexorably approaching a reality.
Cultivation, extraction then destruction
The company has invested in state-of-the-art facilities to ensure a safe and controlled environment for growing cannabis and being able to work in the European market. With its background in horticultural LEDs, Delled – LaFleur therefore cultivates its Cannabis plants, with a proprietary system for controlling the growing environment and drying called Hortimind.
Extraction was also done in-house to obtain a pure, highly concentrated medical cannabis extract. This method not only preserves the therapeutic properties of the plant, but also eliminates unwanted impurities.
Delled – LaFleur has also implemented rigorous quality control measures throughout the production process. Each batch of medical cannabis extract undergoes extensive testing for cannabinoid content, terpene profiles, microbial contaminants, heavy metals and residual solvents. It thus controls these variables in its raw materials by high-performance liquid chromatography (HPLC) and by gas chromatography (GC-MS), a service that it already offers to companies that would like to have their flowers or their CBD extracts.
The batches were then “released,” jargon for meaning that the batches are certified by a qualified person and could be distributed to patients. As medical cannabis is not yet widespread in France, and the experimentation is supplied abroad, part of these technical batches will therefore be destroyed. The other part will be integrated into technical batches of an oral formulation to stabilize them and observe the behavior of the product over time, in particular the degradation of the active ingredients present. The data collected will then be sent to the National Agency for the Safety of Medicines and Health Products (ANSM) to validate the products for post-experimentation.
Delled – LaFleur thus successfully carried out a Proof of concept of its capabilities and shows that it is already able to supply its first batches of medical cannabis to French patients.
